Topic: National Cancer Research Network
Conditions
Interventions
The trial runs for 4 months with no patient follow up after that period. Three arms of the trial are treatment at home, treatment at a designated outreach surgery and at hospital day unit - this can b
Sponsors
Cambridge University Hospitals NHS Foundation Trust (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Any cancer patient being treated at either Cambridge University Hospital (CUH) or West Suffolk Hospital (WSH) 2. Prepared to be considered for treatment at home or at one of the three defined outreach surgeries as alternatives to standard hospital treatment 3. Life expectancy greater than 6 months 4. Either commencing a course of treatment planned to last a minimum of 3 months, or having already commenced a course of treatment which is planned to continue for a minimum of 3 further months 5. Course of treatment may be aimed at cure, palliation or supportive care 6. Has hot and cold running water 7. Has an indoor toilet 8. Has a working telephone 9. Is not dependant on hospital transport 10. Able to give written informed consent 11. Aged greater than 18 years 12. No other acute or chronic medical or psychiatric conditions which might have a significant influence on choice of the appropriate location of the patient to receive treatment 13. Easter Cooperative Oncology Group (ECOG) performance status less than 2; if ECOG PS 2, there must be a second individual living in the home who functions as a carer 14. Either sex, lower age limit of 18 years
Exclusion criteria
Exclusion criteria: 1. Any patient receiving an unlicensed cancer drug treatment as part of a clinical trial, where the drug is defined as an investigational medical product (IMP), unless the trial itself has received ethics and research and development approval to be conducted in designated community settings used in the Outreach Trial 2. Patients with language barriers or communication difficulties whose safety might potentially be compromised by entry into this trial (in the opinion of the Investigator) 3. Any patient, where, in the opinion of the investigator, entry into this trial would give cause for concern regarding patient safety
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patient perceived benefits, measured by questionnaire at 0 weeks, 4 weeks, 8 weeks and 12 weeks with an optional 24 weeks visit. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Additional patient perceived benefits, measured by questionnaire at 0 weeks, 4 weeks, 8 weeks and 12 weeks with an optional 24 weeks visit 2. Impact on costs, measured by questionnaire at 0 weeks and 12 weeks | — |
Countries
England, United Kingdom
Outcome results
None listed